A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
BeOne Medicines
BeOne Medicines
Bristol-Myers Squibb
Swiss Cancer Institute
Janssen Research & Development, LLC
AstraZeneca
M.D. Anderson Cancer Center
Gustave Roussy, Cancer Campus, Grand Paris
H. Lee Moffitt Cancer Center and Research Institute
Arcus Biosciences, Inc.
AstraZeneca
Taipei Veterans General Hospital, Taiwan
Wake Forest University Health Sciences
Gilead Sciences
Hoffmann-La Roche
AstraZeneca
Thomas Jefferson University
Hackensack Meridian Health
Merck Sharp & Dohme LLC
Massachusetts General Hospital
Hoffmann-La Roche
BeOne Medicines
Guangzhou Medical University
TJ Biopharma Co., Ltd.
Tianjin Medical University Cancer Institute and Hospital
University of Pittsburgh
Dana-Farber Cancer Institute
Beijing Cancer Prevention & Treatment Society
Sun Yat-sen University
University Health Network, Toronto
Mario Negri Institute for Pharmacological Research
Università Vita-Salute San Raffaele
CSPC Megalith Biopharmaceutical Co.,Ltd.
Mayo Clinic
NRG Oncology
Lantern Pharma Inc.
Intergroupe Francophone de Cancerologie Thoracique
Memorial Sloan Kettering Cancer Center
Weill Medical College of Cornell University
Bristol-Myers Squibb
Genfleet Therapeutics (Shanghai) Inc.
Genelux Corporation
BeiGene
University of Alabama at Birmingham
University Hospital, Essen
iTeos Therapeutics
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Fudan University
Jiangsu HengRui Medicine Co., Ltd.
Shanghai Junshi Bioscience Co., Ltd.
Iovance Biotherapeutics, Inc.